Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, parallel group, dose ranging study of subcutaneous
methylnaltrexone to be conducted in patients with advanced medical illness and poorly
controlled opioid induced constipation. Patients will be randomized to one of three fixed
dose levels of SC MNTX.
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.